Pygeum: Benefits, Dosage, and What the Research Says

Pygeum is a standardized bark extract derived from Prunus africana (formerly classified as Pygeum africanum), a tall evergreen tree native to sub-Saharan Africa, Madagascar, and the highlands of central and eastern Africa. The tree is sometimes called the African cherry or African plum. Traditional healers across parts of southern and central Africa have used powdered or boiled bark preparations for centuries to support urinary and bladder comfort.

In the 1960s, European pharmaceutical researchers began isolating the bark's active lipophilic constituents and developing standardized extracts. The resulting product was commercialized under brand names such as Tadenan and Pygeum 100, eventually gaining regulatory approval as a phytomedicine in France and several other European countries for lower urinary tract symptoms associated with an aging prostate. Today, Pygeum is widely sold in the United States as a dietary supplement.

Pygeum bark contains three primary classes of bioactive compounds identified through chemical analysis:¹¹

• Phytosterols -- primarily beta-sitosterol, a plant sterol with anti-inflammatory properties. Some commercial extracts contain over 10,000 micrograms per gram of beta-sitosterol, compared to roughly 680 micrograms per gram in raw bark, reflecting concentration during processing.¹¹
• Pentacyclic triterpenes -- including ursolic acid and oleanolic acid, compounds associated with anti-edematous and anti-inflammatory activity in connective tissue.
• Ferulic acid esters -- long-chain fatty alcohols (n-docosanol, tetracosanol) linked to modulation of hormonal secretion in prostate tissue. Ferulic acid is present largely in ester form (greater than 90%) in both raw bark and commercial extracts.¹¹

Commercial products are typically standardized to a specified total sterol percentage. This standardization matters because concentrations of active compounds can vary considerably between raw plant material and finished products, as well as among different brands.

A note on naming: You will see this ingredient listed as both Pygeum africanum and Prunus africana. The plant is the same; the scientific name was reclassified. Products labeled either way are botanically equivalent, though chemical composition can still differ by extraction method and growing region.

Pygeum's effects on prostate and urinary function appear to involve several complementary mechanisms identified through laboratory, cell culture, and animal studies. No single compound fully accounts for the extract's observed clinical activity -- the current scientific understanding points to synergy among multiple phytochemical classes.

Anti-inflammatory pathway

Beta-sitosterol and related phytosterols inhibit the synthesis of pro-inflammatory prostaglandins and reduce the production of 5-lipoxygenase (5-LOX) metabolites in prostate tissue. A 2024 in vitro study using lipopolysaccharide-stimulated human peripheral blood mononuclear cells confirmed that a standardized Pygeum bark extract significantly reduced interleukin-6 (IL-6) levels in three of four human donors tested, and suppressed TNF-alpha across all donors -- two cytokines implicated in chronic prostatic inflammation.⁷

Androgen receptor modulation

A compound called N-butylbenzene-sulfonamide (NBBS), isolated from Pygeum bark, has been shown in cell studies to act as a selective androgen receptor (AR) antagonist. It binds to the androgen receptor protein and blocks its translocation into the cell nucleus, thereby reducing androgen-driven signaling in prostate tissue and suppressing PSA expression in prostate cancer cell lines.⁸ One chemical analysis found that NBBS was not detectable in all commercial Pygeum products tested,¹¹ raising an open question about whether this mechanism operates in all consumer supplements at typical doses.

Inhibition of stromal cell proliferation

Both cell culture and animal studies have demonstrated that Pygeum extract inhibits growth factor-mediated proliferation of prostate stromal cells -- the fibroblasts and myofibroblasts that contribute to tissue enlargement in benign prostatic hyperplasia.¹³¹⁴ Specifically, the extract downregulates transforming growth factor beta-1 (TGF-beta1) expression and inhibits fibroblast growth factor 2 (FGF-2) signaling, two pathways that promote excess prostate tissue growth.¹⁴

Bladder smooth muscle effects

Early pharmacological research suggested that Pygeum may also exert direct relaxing effects on bladder smooth muscle, potentially supporting improved urinary flow through a pathway that is independent of prostate size changes.¹³

Important caveat: Virtually all mechanism data currently available comes from in vitro (cell culture) and animal models. How these mechanisms translate to the human body -- and which are most clinically significant -- has not been definitively established. Clinical trials measure symptom and flow outcomes rather than these molecular endpoints, so the precise chain from compound to clinical effect remains partially inferred.

The most extensively researched application of Pygeum is supporting healthy urinary flow and comfort in aging men. The clinical evidence base consists of randomized controlled trials (RCTs) conducted primarily in Europe from the 1970s through the early 2000s, when Pygeum extract was being evaluated as a regulated phytomedicine rather than a dietary supplement. This regulatory context influenced the rigor of the trials, many of which were double-blind and placebo-controlled.

What the research shows

The cornerstone of the evidence is a 2000 systematic review and quantitative meta-analysis by Ishani et al., which identified 18 RCTs involving 1,562 men and pooled their results.¹ Compared with placebo, Pygeum extract provided a moderately large improvement in combined urologic symptoms and urinary flow measures. Key pooled estimates include:

• Men were more than twice as likely to report overall symptom improvement (risk ratio 2.1; 95% CI: 1.40 to 3.1)¹
• Nocturia (nighttime urination) was reduced by approximately 19% versus placebo¹
• Residual urine volume decreased by approximately 24%¹
• Peak urine flow rate increased by approximately 23%¹

A 2002 Cochrane systematic review by Wilt et al. covering the same trial database reached a consistent conclusion: Pygeum extract produced meaningful improvements in urinary symptoms and flow measures, with adverse effects mild and comparable in frequency to placebo, and similar dropout rates between groups (13% active versus 11% placebo).²

Among the individual trials within this body of evidence, a placebo-controlled double-blind study across 8 centers in Germany, France, and Austria enrolled 263 men and administered 50 mg of Pygeum extract twice daily for 60 days. The result: micturition improvement was reported by 66% of the Pygeum group versus 31% in the placebo group (p less than 0.001), with statistically significant differences on objective measures including uroflowmetry and residual urine volume.³

A separate RCT by Chatelain et al. (1999) compared 50 mg twice daily versus 100 mg once daily in a two-month blinded comparison followed by a 10-month open-label extension. The International Prostate Symptom Score (IPSS) improved by 38% and 35% in the two groups respectively, quality-of-life scores improved by 28% in both groups, and maximum urine flow rose by 16 to 19%. After the full 12-month period, IPSS scores continued to decline from a baseline of 16 to approximately 9, with roughly half of participants achieving scores below 8.⁴

An open multicenter study across the Czech Republic, Slovakia, and Poland enrolled 85 men and found IPSS improvement of 40%, quality-of-life improvement of 31%, and a 32% reduction in nocturia, with no treatment-related adverse effects observed.⁵ A real-world cross-sectional study in Spain (the PROFIT study, 2022) added post-market observational data: 60% of 206 patients with BPH-related symptoms achieved a clinically meaningful IPSS reduction of at least 4 points after six months, and the proportion reporting significant quality-of-life impairment fell from 45.2% to 22.6%.⁶

Honest assessment of the evidence: The clinical evidence is genuine and among the strongest published for any botanical prostate supplement. However, the 2000 meta-analysis noted important limitations: the average study duration was only 64 days, only one trial reported adequate allocation concealment, preparations and doses varied across studies, and most trials did not use modern standardized outcome instruments like the IPSS.¹ Longer-term, methodologically rigorous trials using current reporting standards would strengthen the evidence considerably. This extract also has not been compared head-to-head to standard pharmaceutical options such as alpha-blockers or 5-alpha-reductase inhibitors.

Chronic low-grade inflammation of the prostate is increasingly recognized in the urological literature as a contributor to lower urinary tract symptoms. Pygeum's constituent compounds appear to target this inflammatory pathway through multiple mechanisms identified in cell and tissue research.

What the research shows

A 2024 in vitro study (Villar et al.) exposed lipopolysaccharide-stimulated human peripheral blood mononuclear cells from four donors to a standardized Pygeum bark extract (Prunera) at multiple concentrations.⁷ The extract produced statistically significant reductions in IL-6 -- a key mediator of chronic prostatic inflammation -- in three of four donors tested, with dose-dependent suppression. Additional reductions were observed across most donors in IL-2, IL-27, TNF-alpha, IL-4, IL-5, IL-9, and IL-13, suggesting broad modulation of the pro-inflammatory cytokine network relevant to prostate tissue health.

Complementary cell studies have demonstrated that Pygeum extract inhibits proliferation of the fibroblasts and myofibroblasts that drive prostate tissue expansion in BPH, acting via downregulation of TGF-beta1 expression and FGF-2 signaling.¹⁴ In a prostate cancer cell line model, NBBS from Pygeum bark suppressed androgen receptor nuclear translocation and PSA expression.⁸ In animal studies using TRAMP mice -- a model prone to prostate cancer -- Pygeum extract-fed animals developed prostate tumors at a rate of 35% versus 62.5% in controls, though this finding must be interpreted with caution as an animal model result.⁹

Evidence context: All anti-inflammatory and anti-proliferative data presented here come from in vitro or animal models. Human clinical trials specifically designed to measure inflammatory biomarkers or tissue-level effects have not been published. These findings provide plausible mechanistic explanations for the clinical trial results but are not, by themselves, proof of benefit in humans. Preclinical data only -- human evidence not established for these specific pathways.

A smaller secondary body of research has examined Pygeum's potential effects on prostatic secretory function, which contributes to semen composition and plays a role in male reproductive health.

What the research shows

A 1984 study by Lucchetta et al. evaluated Pygeum treatment in men with measurably reduced prostatic acid phosphatase activity -- a biochemical marker of diminished prostate secretion.¹⁰ Treatment was associated with increased acid phosphatase levels and total protein content in seminal fluid. The researchers observed that men without evidence of concurrent prostate inflammation responded more consistently, suggesting that Pygeum may support prostatic secretory function most effectively when underlying infection or active inflammation is absent.

Evidence context: This area of research rests on a single older study conducted before modern reproductive outcome standardization. No modern RCTs have examined the impact of Pygeum on fertility endpoints, sperm parameters, or seminal fluid volume in controlled settings. While the mechanism is plausible given Pygeum's known effects on prostate glandular tissue, any potential benefit in this area should be considered preliminary and hypothesis-generating only.